Last Update 22 Mar 26

Fair value Increased 0.93%

ASTH: Future Full-Risk Platform Execution Will Highlight Underappreciated Value-Based Care Upside

Astrana Health's analyst fair value estimate has edged up from $35.67 to $36.00 as analysts factor in updated assumptions around discount rates, profit margins, and a lower future P/E multiple, informed by recent Street research, including adjusted price targets and views on its role as a growing value-based care platform.

Analyst Commentary

Recent Street research around Astrana Health focuses on how its role as a value-based care platform could influence both upside potential and execution risk. Price target adjustments, together with commentary around the latest 10-K, provide a window into how analysts are framing valuation, growth expectations, and the durability of the current business model.

Bullish Takeaways

Bullish analysts point to the 10-K as support for the view that Astrana is developing into a larger and more relevant value-based care platform, which they see as important for justifying a higher long-term valuation multiple.
The lift in one Street price target to US$38, even with a lower future P/E assumption in the updated fair value work, is interpreted as a sign of confidence that the business model can support earnings power that aligns with or exceeds current expectations.
Supportive commentary around Astrana's positioning in value-based care suggests that, if management executes on scaling the platform efficiently, revenue and profit pools tied to this model could remain a key part of the equity story.
Bullish analysts see the combination of adjusted discount rates and profitability assumptions as still consistent with an investment case where execution on current plans is sufficient to support the revised US$36.00 fair value estimate.

Bearish Takeaways

The mention of a lower future P/E multiple in the updated valuation framework indicates that some analysts are building in more conservative assumptions around how the market might value Astrana's earnings, even if the fundamental thesis remains intact.
The recent reduction of one Street price target by US$5, although details are limited, indicates that not all analysts see the risk or reward as skewed in the same direction, and some are more cautious on execution or profitability.
More bearish views focus on the possibility that scaling a value-based care platform may come with pressure on near- to medium-term margins, which could limit upside if cost discipline or contract performance does not track current expectations.
More cautious analysts highlight that the fair value increase from US$35.67 to US$36.00 is modest, framing the current setup as one where much of the perceived value from the platform model could already be reflected in valuation.

What's in the News

Astrana Health reported that from October 1, 2025 to December 31, 2025 it repurchased 633,844 shares, representing 1.28% of shares, for US$16.75 million, completing a total of 903,925 shares, or 1.86%, for US$26.29 million under the buyback announced on December 15, 2022 (Key Developments).
On March 2, 2026, the company increased its equity buyback authorization by US$50 million, bringing total repurchase capacity to US$100 million (Key Developments).
Astrana Health announced that it expects total revenue of US$900 million to US$1,000 million for the three months ending March 31, 2026, and US$3.8 billion to US$4.1 billion for the year ending December 31, 2026 (Key Developments).
On March 2, 2026, the company disclosed that it will be unable to file its next 10-K by the SEC deadline (Key Developments).

Valuation Changes

Fair Value, adjusted slightly higher from $35.67 to $36.00.
Discount Rate, trimmed from 7.51% to 7.28%, indicating a modest shift in the required return used in the model.
Revenue Growth, moved from 13.81% to 13.43%, reflecting a small change in top line expectations built into the assumptions.
Net Profit Margin, raised from 1.49% to 2.41%, pointing to meaningfully higher modeled profitability.
Future P/E, reduced from 34.86x to 19.05x, signaling a much more conservative multiple assumption on forward earnings.

3 views

Key Takeaways

Transition to value-based care contracts and strategic acquisitions are driving higher-quality revenue, improved retention, and positioning the company for sustainable growth.
Investments in proprietary technology and operational integration support better cost control, margin expansion, and increased competitiveness in a changing healthcare landscape.
Heavy reliance on government programs, integration challenges, competitive pressures, and rising regulatory costs threaten Astrana Health's profitability, growth, and long-term financial stability.

Catalysts

About Astrana Health

A healthcare management company, provides medical care services in the United States.What are the underlying business or industry changes driving this perspective?

Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention, positioning Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages-likely supporting both revenue growth and sustainable margin expansion over time.
Sustained investment and rapid integration of proprietary technology platforms and data infrastructure (including AI-driven capabilities) are enabling better cost control, real-time utilization management, and operational leverage, which should contribute to further EBITDA margin expansion as scale increases and as new geographies ramp.
Astrana's acquisition and successful early integration of Prospect Health are creating potential for significant operational synergies ($12–$15M targeted over 12–18 months, with upside), broader scale, and increased bargaining power with payers, all of which are expected to enhance top-line growth and earnings power going forward.
Long-term tailwinds from regulatory and payer shifts towards alternative payment models and value-based healthcare are expanding the addressable market and favor operators with mature, risk-bearing platforms like Astrana, setting the stage for durable revenue and profit growth as national healthcare expenditure rises.
The ability to consistently deliver industry-leading medical cost trend control and build trusted partnerships with payers differentiates Astrana from competitors and should support higher contract renewal rates, lower member churn, and net margin resilience even in volatile or cost-constrained healthcare environments.

Astrana Health Earnings and Revenue Growth

Astrana Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Astrana Health's revenue will grow by 13.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.7% today to 2.4% in 3 years time.
Analysts expect earnings to reach $112.0 million (and earnings per share of $2.21) by about March 2029, up from $22.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.1x on those 2029 earnings, down from 53.3x today. This future PE is lower than the current PE for the US Healthcare industry at 21.2x.
Analysts expect the number of shares outstanding to decline by 0.92% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Astrana Health's substantial Medicaid exposure (about 28–30% of revenue) faces long-term risk from legislative and funding changes (e.g., One Big Beautiful Bill Act) and demographic shifts (e.g., changes in eligibility and undocumented populations), potentially driving lower enrollment, unfavorable acuity mix, and mid-single-digit margin compression-directly impacting revenue growth and net margins.
Heavy reliance on government payers (Medicare Advantage and Medicaid) creates significant reimbursement rate risk; policy changes or rate increases not keeping pace with medical or utilization trends could pressure long-term earnings and lead to more volatile profitability.
Execution risk exists in integrating large acquisitions such as Prospect Health, especially achieving targeted synergies, standardizing operations, and technology adoption-failure to deliver or unforeseen costs could dilute net margins and EBITDA progression.
Consolidation and intensifying competition from larger, tech-enabled, or better-capitalized health systems may limit Astrana Health's pricing power, contract rates, and patient/member growth, straining both top-line expansion and operating earnings over time.
Anticipated ongoing increases in regulatory scrutiny, compliance costs (including data privacy and value-based care complexity), and healthcare consumer price sensitivity could cap price increases and raise expenses-compressing free cash flow and long-term profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $36.0 for Astrana Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $26.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.6 billion, earnings will come to $112.0 million, and it would be trading on a PE ratio of 19.1x, assuming you use a discount rate of 7.3%.
Given the current share price of $24.23, the analyst price target of $36.0 is 32.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Astrana Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Value Based Care And Data Integration Will Advance US Healthcare